XML 38 R29.htm IDEA: XBRL DOCUMENT v3.22.2.2
Revenue Recognition and Accounts Receivable (Tables)
 9 Months Ended
Sep. 30, 2022
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue
The following table presents the Company’s net sales by product category for each of our reportable segments for the three and nine months ended September 30, 2022 and 2021, respectively:

(In millions)Three Months Ended September 30, 2022
Product CategoryDeveloped MarketsGreater ChinaJANZEmerging MarketsTotal
Brands$1,327.7 $571.9 $211.6 $429.1 $2,540.3 
Complex Gx and Biosimilars295.0 0.2 10.9 14.1 320.2 
Generics808.8 1.9 160.5 235.7 1,206.9 
Total$2,431.5 $574.0 $383.0 $678.9 $4,067.4 

(In millions)Nine Months Ended September 30, 2022
Product CategoryDeveloped MarketsGreater ChinaJANZEmerging MarketsTotal
Brands$3,931.8 $1,687.9 $703.7 $1,254.1 $7,577.5 
Complex Gx and Biosimilars986.1 0.5 33.3 45.9 1,065.8 
Generics2,468.8 7.0 496.9 735.0 3,707.7 
Total$7,386.7 $1,695.4 $1,233.9 $2,035.0 $12,351.0 

(In millions)Three Months Ended September 30, 2021
Product CategoryDeveloped MarketsGreater ChinaJANZEmerging MarketsTotal
Brands$1,522.7 $566.8 $299.1 $414.5 $2,803.1 
Complex Gx and Biosimilars305.1 — 13.2 13.7 332.0 
Generics828.1 — 193.0 364.3 1,385.4 
Total$2,655.9 $566.8 $505.3 $792.5 $4,520.5 

(In millions)Nine Months Ended September 30, 2021
Product CategoryDeveloped MarketsGreater ChinaJANZEmerging MarketsTotal
Brands$4,350.5 $1,706.9 $878.5 $1,293.5 $8,229.4 
Complex Gx and Biosimilars926.4 — 31.9 35.4 993.7 
Generics2,591.0 2.1 577.8 1,088.3 4,259.2 
Total$7,867.9 $1,709.0 $1,488.2 $2,417.2 $13,482.3 
____________
(a)Amounts for the three and nine months ended September 30, 2022 include the unfavorable impact of foreign currency translations compared to the prior year period.
The following table presents net sales on a consolidated basis for select key products for the three and nine months ended September 30, 2022 and 2021:
Three months ended September 30,
Nine months ended September 30,
(In millions)2022202120222021
Select Key Global Products
Lipitor ®
$420.4 $410.0 $1,266.1 $1,272.9 
Norvasc ®189.3 198.4 600.1 635.9 
Lyrica ®156.5 175.6 483.9 555.9 
Viagra ®117.0 138.0 361.9 412.4 
EpiPen® Auto-Injectors114.4 129.5 309.7 337.3 
Celebrex ®
82.2 86.0 253.4 257.3 
Creon ®76.4 81.1 226.5 231.7 
Effexor ®
64.2 79.5 215.4 239.6 
Zoloft ®
53.1 61.3 188.7 208.8 
Xalabrands51.0 55.8 146.7 172.0 
Select Key Segment Products
Influvac ®$159.3 $161.2 $178.3 $165.3 
Yupelri ®53.4 39.4 146.1 118.1 
Amitiza ®39.4 49.5 125.3 147.5 
Dymista ®38.6 35.0 138.0 129.9 
Xanax ®38.3 47.6 115.5 141.5 
____________
(a)The Company does not disclose net sales for any products considered competitively sensitive.
(b)Products disclosed may change in future periods, including as a result of seasonality, competition or new product launches.
(c)Amounts for the three and nine months ended September 30, 2022 include the unfavorable impact of foreign currency translations compared to the prior year period.
Variable Consideration and Accounts Receivable
The following table presents a reconciliation of gross sales to net sales by each significant category of variable consideration during the three and nine months ended September 30, 2022 and 2021, respectively:
Three Months EndedNine Months Ended
September 30,September 30,
(In millions)2022202120222021
Gross sales$6,862.9 $7,739.5 $21,069.9 $23,058.8 
Gross to net adjustments:
Chargebacks(1,553.1)(1,439.3)(4,731.5)(4,112.1)
Rebates, promotional programs and other sales allowances(1,021.8)(1,521.6)(3,303.0)(4,656.7)
Returns(73.4)(87.9)(238.7)(289.2)
Governmental rebate programs(147.2)(170.2)(445.7)(518.5)
Total gross to net adjustments$(2,795.5)$(3,219.0)$(8,718.9)$(9,576.5)
Net sales$4,067.4 $4,520.5 $12,351.0 $13,482.3 
Schedule of Accounts Receivable, Net Such allowances were comprised of the following at September 30, 2022 and December 31, 2021, respectively:
(In millions)September 30,
2022		December 31,
2021
Accounts receivable, net$1,788.4 $1,688.6 
Other current liabilities837.2 1,362.1 
Total$2,625.6 $3,050.7 
Accounts receivable, net was comprised of the following at September 30, 2022 and December 31, 2021, respectively:
(In millions)September 30,
2022		December 31,
2021
Trade receivables, net$2,829.8 $3,774.4 
Other receivables504.1 492.0 
Accounts receivable, net$3,333.9 $4,266.4